Screening HIV-infected patients for non-AIDS-defining malignancies
- Adrienne A. PhillipsAffiliated withDepartment of Medicine, Harlem Hospital Center, Columbia University College of Physicians and Surgeons Email author
- , Jessica E. Justman
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The use of antiretroviral therapy has reduced mortality and shifted the spectrum of malignancies affecting people living with HIV/AIDS (PLWH). We review guidelines and evidence for screening PLWH for non-AIDS-defining malignancies as compared with the general population. Cervical cancer screening clearly differs for HIV-seropositive women, with two Pap tests 6 months apart in the first year and then annually if normal. The role of cervical human papillomavirus screening has not yet been defined in HIV-seropositive women. Anal cancer screening consists of an annual digital rectal examination, and some (but not all) guidelines also recommend annual anal Pap tests. Screening for breast and colorectal cancer should follow standard, age-appropriate screening recommendations that apply to the general population. Screening HIV-infected men for prostate cancer, as with the general population, lacks a clear benefit. Despite increasing rates of hepatocellular carcinoma and lung cancers among PLWH, there is insufficient evidence to support routine screening.
- Screening HIV-infected patients for non-AIDS-defining malignancies
Current HIV/AIDS Reports
Volume 6, Issue 2 , pp 83-92
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links